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Abstract
Background: Ameloblastoma is a frequent odontogenic benign tumor characterized by local
invasiveness, high risk of recurrence and occasional metastasis and malignant transformation.
Matrix metalloproteinase-2 (MMP-2) promotes tumor invasion and progression by destroying the
extracellular matrix (ECM) and basement membrane. For this proteolytic activity, the endogenous
inhibitor is reversion-inducing cysteine rich protein with Kazal motifs (RECK). The aim of this study
was to characterize the relationship between RECK and MMP-2 expression and the clinical
manifestation of ameloblastoma.
Methods: Immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR)
were employed to detect the protein and mRNA expression of RECK and MMP-2 in keratocystic
odontogenic tumor (KCOT), ameloblastoma and ameloblastic carcinoma.
Results: RECK protein expression was significantly reduced in KCOT (87.5%), ameloblastoma
(56.5%) and ameloblastic carcinoma (0%) (P < 0.01), and was significantly lower in recurrent
ameloblastoma compared with primary ameloblastoma (P < 0.01), but did not differ by histological
type of ameloblastoma. MMP-2 protein expression was significantly higher in ameloblastoma and
a m e l o b l a s t i c  c a r c i n o m a  c o m p a r e d  w i t h  K C O T  ( P  <  0 . 0 1 ) .  R E C K  m R N A  e x p r e s s i o n  w a s
significantly lower in ameloblastoma than in KCOT (P < 0.01), lower in recurrent ameloblastoma
than in primary ameloblastoma, and was negative in ameloblastic carcinoma. MMP-2 mRNA
expression was significantly higher in ameloblastoma compared with KCOT (P < 0.01), but was no
different in recurrent ameloblastoma versus primary ameloblastoma. RECK protein expression was
negatively associated with MMP-2 protein expression in ameloblastoma (r = -0.431, P < 0.01).
Conclusion: Low or no RECK expression and increased MMP-2 expression may be associated
with negative clinical findings in ameloblastoma. RECK may participate in the invasion, recurrence
and malignant transformation of ameloblastoma by regulating MMP-2 at the post-transcriptional
level.
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Background
Odontogenic tumors arise from epithelial, ectomesenchy-
mal or mesenchymal elements that are, or have been, part
of the tooth-forming apparatus. Ameloblastoma is a com-
mon odontogenic neoplasm estimated to form 36% of all
odontogenic tumors in China [1]. Although classified as
benign, its locally invasion, distant metastasis and malig-
nant transformation pose a therapeutic challenge in oral
and maxillofacial surgery [2]. A better understanding of
the molecular mechanisms of ameloblastoma progression
may inform the search for adjuvant therapies.
Matrix metalloproteinases (MMPs) play an important role
in ameloblastoma invasion, since they are involved in
breakdown of the extracellular matrix (ECM) [3]. Among
MMPs, MMP-2 has been closely associated with amelob-
lastoma invasion [4,5]. Reversion-inducing cysteine rich
protein with Kazal motifs (RECK) was initially discovered
due to its ability to induce reversion in ras-activated
fibroblasts. The key action of RECK is to inhibit MMPs,
especially MMP-2 and MMP-9 [6]. For this reason, it is
important in embryogenesis and other physiological
processes. Furthermore, it significantly limits invasion of
tumors and inhibits MMP-2. For instance, RECK expres-
sion in pancreatic cancer tissue was significantly lower
than in adjacent normal tissues and was negatively associ-
ated with MMP-2 activation and tumor invasive ability
[7]. Restoring RECK expression in human fibrosarcoma
HT1080 cells reduced both their invasive ability and the
amount of active MMP-2 [8]. To date, no relationship
between MMP-2 and RECK in benign ameloblastoma has
been documented. Therefore, this study investigated the
combinatorial role and association of RECK and MMP-2
in ameloblastoma.
Methods
Patients and Tumor Samples
Formalin-fixed paraffin-embedded specimens (dating
from 1999 to 2008) were retrieved from the Pathology
Service of the Second Affiliated Hospital of Sun Yat-Sen
University. Studied were specimens from 69 cases of
ameloblastoma (45 males and 24 females; mean age 31.6
years, range 9-72 years; primary cases 45, recurrent cases
24), 6 cases of ameloblastic carcinoma and 16 cases of
keratocystic odontogenic tumor (KCOT). The 69 amelob-
lastoma cases included 22 plexiform ameloblastomas, 29
follicular ameloblastomas, seven unicystic ameloblasto-
mas, four acanthomatous ameloblastomas, three granular
cell ameloblastomas and four desmoplastic ameloblasto-
mas. The paraffin embedded tissue samples were cut and
mounted on glass slides for immunohistochemical analy-
sis.
In addition, fresh specimens, surgically removed from
patients with epithelial odontogenic tumors at the
Department of Oral and Maxillofacial Surgery of the Sec-
ond Affiliated Hospital of Sun Yat-Sen University from
March 2007 to December 2008, were collected. The fresh
specimens included 22 cases of ameloblastoma (14 males
and 8 females; mean age 34.9 years, range 13-72 years;
primary cases 12, recurrent cases 10), 2 cases of amelob-
lastic carcinoma and 16 cases of KCOT. The 22 ameloblas-
toma cases included eight plexiform ameloblastomas, ten
follicular ameloblastomas, two unicystic ameloblasto-
mas, one granular cell ameloblastoma and one desmo-
plastic ameloblastoma. All fresh tissues were immediately
stored in liquid nitrogen for further analysis. Among these
cases, ameloblastic carcinomas and KCOT were used as
controls. Diagnosis and classification of all specimens was
confirmed by histopathologic examination according to
the WHO classification. All patients gave written
informed consent, and the approval of the Sun Yet-sen
University Ethics Committee was obtained.
Immunohistochemical staining
Immunohistochemical staining was performed using the
2-step plus poly-HRP method as described previously [9].
Briefly, one representative section of the tissue was cut at
4 μm and placed on poly-L-lysine coated slides. The slides
were deparaffinized, rehydrated, immersed in 10 mM
sodium citrate buffer (pH 6.0) and pretreated in a micro-
wave oven for 10 min, followed by a 10-minute rinse with
phosphate-buffered saline (PBS). After blocking with 3%
hydrogen peroxide for 10 min at room temperature, the
slides were incubated at 4°C overnight with primary anti-
bodies: anti-RECK (1:50 goat monoclonal antibody,
Santa Cruz Biotechnology, Inc. Santa Cruz, CA) and anti-
MMP-2 (1:200 mouse monoclonal antibody, Santa Cruz
Biotechnology, Inc. Santa Cruz, CA). Afterwards, the
slides were stained with the 2-step plus Poly-HRP Anti-
Goat IgG Detection System (ZSGB-Bio, Beijing, China) for
RECK or 2-step plus Poly-HRP Anti-Mouse IgG Detection
System (ZSGB-Bio, Beijing, China) for MMP-2. After visu-
alization of the reaction with the DAB chromogen, the
slides were counterstained with haematoxylin and cov-
ered with a glycerin gel. As positive controls, a colon can-
cer specimen was used for RECK and a breast cancer
specimen for MMP-2 (patient consent obtained). Nega-
tive controls consisted of tissue sections incubated with
PBS instead of the primary antibody.
Evaluation of immunohistochemical staining
Sections were evaluated by two blinded, experienced
investigators who provided a consensus opinion of stain
patterns by light microscopy. Immunohistochemical
staining of cells was assessed according to stain intensity
and proportion of cells stained. Stain intensity was graded
using a 4-point scale: 0, no staining; 1, mild staining; 2
moderate staining; and 3, intense staining. The propor-
tion of cells stained was assessed using a semiquantitativeBMC Cancer 2009, 9:427 http://www.biomedcentral.com/1471-2407/9/427
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4-point scale: 0, no cell staining in any microscopic fields;
1, <25% staining; 2, 25-50% staining; and 3, >50% stain-
ing. The combined score (extension plus intensity) was
assessed as follows: <2, negative staining or low staining
(-); 2 and 3, moderate staining (+); and ≥4, strong staining
(++). A combined score equaling or exceeding (+) was
defined as positive for RECK and MMP-2.
Reverse transcription-polymerase chain reaction (RT-
PCR) and image analysis
Gene expression studies were conducted using gene-spe-
cific primers for RECK and MMP-2. Total RNA was
extracted from the frozen tissues and subjected to reverse
transcription-polymerase chain reaction (RT-PCR) as fol-
lows. Total RNA from 100 mg tissue samples was
obtained by the Trizol method (GIBCO-BRL, Grand
Island, NY) according to the manufacturer's instructions,
and an Access RT-PCR system (Promega, Madison, WI)
was used to amplify the products. RT-PCR of a single tar-
get RNA was performed in a single tube with Avian Mye-
loblastosis Virus reverse transcriptase (AMV RT) for first-
strand DNA synthesis; Thermus flavus (Tfl) DNA
polymerase for second-strand complementary DNA
(cDNA) synthesis; and 5 M oligodeoxythymidylate, 10
mM deoxynucleoside triphosphate and 1 mM Mg2+ for
DNA amplification in a volume of 50 μL. RT-PCR was per-
formed in a DNA Thermal Cycler 480 (Perkin Elmer
Corp., Norwalk, CT) at the following cycles: 45 min RT at
48°C, 5 min AMV RT inactivation and RNA/cDNA/primer
denaturation at 94°C, 30 sec denaturation at 94°C, 30 sec
annealing at either 59°C (β-acting) or 55°C (RECK,
MMP-2), and a 100 sec (RECK and MMP-2) or 120 sec (β-
acting) extension at 72°C. Thirty (RECK, MMP-2) or 35
(β-acting) cycles were conducted per amplification of each
PCR product. The linear range for PCR conditions was
tested in pilot experiments and was 30-40 cycles for RECK,
MMP-2 and β-acting. All subsequent reactions were car-
ried out within this range.
The PCR products were fractionated by 1.5% agarose gel
electrophoresis (agarose-1000, GIBCO-BRL, Grand
Island, NY) and stained with 0.5 μg/mL ethidium bro-
mide (GIBCO-BRL, Grand Island, NY), and the identity of
the PCR products confirmed using a 100-bp ladder
(Promega, Madison, WI) as the DNA standard. Each PCR
reaction was replicated a minimum of three times. Primer
sequences were: RECK (NM021111): sense-primer 5'-
TAACCAAATGTGCCGTGATG-3', antisense 5'-TCCAAG-
GCAATAGCCAGTTC-3'; MMP-2 (NM004530): sense-
primer 5'-GATGCCGCCTTTAACTGG-3', antisense 5'-
TCAGCAGCCTAGCCAGTCG-3'; and β-acting
(NM001101): sense-primer 5'-GATGAGATTGGCAT-
GGCTTT-3', antisense 5'-CTCAAGTTGGGGGACAAAAA-
3'. Amplification products of the RNAs coding for RECK,
MMP-2 and β-acting were 207, 279, and 431 bp, respec-
tively. Quantitation was performed by densitometry, with
β-acting used as an internal control for RT-PCR reactions
and the products analyzed on a 1.5% agarose minigel sys-
tem. A computerized image analysis system (Kontron
IBAS2.0, Munich, Germany) was used to quantify band
intensity. Results were evaluated as a relative unit deter-
mined by normalization of the optical density (OD) of
RECK or MMP-2 band to that of β-acting band (the ratio
of RECK/β-acting and MMP-2/β-acting, respectively).
Statistical analysis
Results of RECK and MMP-2 protein expression are
described with positive ratio, with differences between
groups tested for significance using Fisher's exact and
Pearson Chi-square tests. RECK and MMP-2 mRNA
expression are expressed as mean ± standard deviation
(SD), and the Wilcoxon rank sum test and T-test were used
to analyze differences in results between groups. The cor-
relation in protein or mRNA expression of RECK and
MMP-2 was analyzed using Spearman's rank correlation.
Statistical analysis was performed using SPSS version 15.0
(SPSS Inc., Chicago, IL). P values < 0.05 were considered
significant.
Results
Expression of RECK and MMP-2 protein in KOCT, 
ameloblastoma and ameloblastic carcinoma
Immunoreactivity for RECK was detected in nearly all epi-
thelial cells of KOCT, in central polyhedral cells of follic-
ular ameloblastoma and in peripheral columnar cells of
plexiform ameloblastoma, but not in ameloblastic carci-
noma cells (Figure 1). RECK expression gradually signifi-
cantly decreased in KCOT (87.5%), ameloblastoma
(56.52%) and ameloblastic carcinoma (0%, P < 0.01),
and was significantly higher in primary ameloblastoma
(71.11%) than in recurrent ameloblastoma (29.17%, P <
0.01), but no significant difference was seen between his-
tological types (Table 1).
Immunoreactivity for MMP-2 was mainly detected in
prickle cells of KCOT, peripheral columnar or cuboidal
cells of ameloblastoma and ameloblastic carcinoma cells
(Figure 2). MMP-2 expression was significantly higher in
ameloblastic carcinoma (100%) and ameloblastoma
(84.06%) than in KCOT (18.75%, P < 0.01), but was not
significantly different in primary ameloblastoma
(82.22%) versus recurrent ameloblastoma (87.5%) or
between histological types (Table 1).
Expression of RECK and MMP-2 mRNA in KOCT, 
ameloblastoma and ameloblastic carcinoma
RECK mRNA was detected in all KCOT and ameloblast-
oma samples, but not in either ameloblastic carcinoma
sample. MMP-2 mRNA was detected in all KCOT, amelob-
lastoma and ameloblastic carcinoma samples, andBMC Cancer 2009, 9:427 http://www.biomedcentral.com/1471-2407/9/427
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strongly expressed in both ameloblastic carcinoma sam-
ples (Figure 3). Because of the lack of ameloblastic carci-
noma cases, their data were not analyzed statistically.
Relative expression levels of RECK mRNA were signifi-
cantly lower in ameloblastoma than in KCOT (P < 0.01),
but significantly higher for MMP-2 mRNA (P < 0.01). In
ameloblastoma, relative expression levels of RECK mRNA
were significantly lower in recurrent ameloblastoma than
in primary ameloblastoma (P < 0.05), but levels of MMP-
2 mRNA did not differ to a statistically significant extent
between recurrent ameloblastoma and primary amelob-
lastoma. Relative expression levels of RECK and MMP-2
mRNA did not differ statistically between follicular amel-
oblastoma and plexiform ameloblastoma (Table 2).
The relationship between RECK and MMP-2 in 
ameloblastoma
In ameloblastoma, protein expression in RECK and MMP-
2 were inversely proportional (r = -0.431, P < 0.01, Table
3), but mRNA expression of RECK and MMP-2 were not
correlated (r = 0.367, P > 0.05).
A representative immunohistochemical reactivity for RECK Figure 1
A representative immunohistochemical reactivity for 
RECK. (A) Keratocystic odontogenic tumor showing strong 
reactivity (× 400); (B) Follicular ameloblastoma showing 
strong reactivity in central polyhedral cells and weak in 
peripheral columnar cells (× 200); (C) Plexiform ameloblast-
oma showing reactivity in peripheral columnar cells and 
nearly no expression in central polyhedral cells (× 200); (D) 
Ameloblastic carcinoma showing no expression in tumor cells 
(× 400).
Table 1: Immunohistochemical reactivity for RECK and MMP-2 
in KCOT, AB and AC
n RECK MMP-2
-+ + + P -+ + + P
KCOT 16 2 5 9 0.000 13 0 3 0.000
AB 69 30 22 17 11 23 35
A C 660 015
Primary AB 45 13 17 15 0.001 8 19 18 0.82
Recurrent AB 24 17 5 2 3 4 17
KCOT; keratocystic odontogenic tumor, AB; ameloblastoma, AC; 
ameloblastic carcinoma.
A representative immunohistochemical reactivity for MMP-2 Figure 2
A representative immunohistochemical reactivity for 
MMP-2. (A) Keratocystic odontogenic tumor showing mod-
erate reactivity in prickle cells (× 400); (B) Follicular amelob-
lastoma showing strong reactivity in peripheral columnar 
cells (× 400); (C) Plexiform ameloblastoma showing strong 
reactivity in peripheral columnar cells (× 200); (D) Amelob-
lastic carcinoma showing strong reactivity in tumor cells (× 
400).
Representative gel pictures showing the mRNA expression  of RECK and MMP-2 Figure 3
Representative gel pictures showing the mRNA 
expression of RECK and MMP-2. M, DNA marker; 1 and 
2, Keratocystic odontogenic tumor; 3 and 4, Ameloblastoma; 
5, Ameloblastic carcinoma.BMC Cancer 2009, 9:427 http://www.biomedcentral.com/1471-2407/9/427
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Discussion
Many studies have verified that MMP-2 plays an impor-
tant role in tumor invasion [10,11]. Our and other studies
also showed that the high expression and activity of MMP-
2 is related to a more aggressive behavior in ameloblast-
oma [4,5,12]. RECK can inhibit MMP-2 expression and
activity as an endogenous inhibitor of MMP-2 in physio-
logical and pathological processes. Previous studies have
shown that high RECK expression can inhibit the invasion
potential of some tumors by inhibiting MMP-2 [7,8].
However, few reports have delineated the combinatorial
role and association of RECK and MMP-2 in ameloblast-
oma.
RECK is an anti-oncogene inversely related to tumor inva-
sion that is downregulated in many tumors. Takeuchi and
colleagues [13] found RECK downregulated in most colon
cancer specimens compared with surrounding normal tis-
sue, and low RECK expression in lymph nodes with a high
metastatic rate. Mori's study showed significant inhibition
of the invasive potential of HT1080 cells and their mutant
Rzmet-2 after being transfected with RECK plasmid [14].
In our study, RECK protein and mRNA expression were
gradually reduced in KCOT, primary ameloblastoma,
recurrent ameloblastoma and ameloblastic carcinoma,
similar to the results by Kumamoto et al. [15], who also
found RECK protein expression downregulated in amel-
oblastoma compared with tooth germ. Our results indi-
cated that the protein expression and the transcriptional
levels of RECK were sequentially lower or absent as odon-
togenic tumor cells increased in aggressiveness, indicating
that RECK expression levels may be correlated with clini-
cal outcomes in ameloblastoma.
RECK may inhibit tumor invasion and metastasis by
inhibiting the expression and activity of MMP-2. MMP-2
is one of the most important proteolytic enzymes that
degrade basement membrane and extracellular matrix
during tumor invasion and metastasis [16]. Increased
expression and activity of MMP-2 could promote tumor
invasion ability [17-19]. Similar findings have been
described in our and other studies of ameloblastoma,
indicating that high MMP-2 expression and activity is
related to a more aggressive infiltrative behavior in amel-
oblastoma [4,5,12]. Our study showed that MMP-2 pro-
tein expression and transcriptional levels sequentially
increased in KCOT, ameloblastoma and ameloblastic car-
cinoma, and expression levels of MMP-2 protein and
mRNA were significantly higher in ameloblastoma than
in KOCT, or just the opposite of RECK, indicating that
MMP-2 protein expression and transcription sequentially
increased with the aggressiveness of odontogenic tumor
cells. These results demonstrate that increased MMP-2
expression may be implicated in poor clinical prognosis
and may be relation to lower or even no expression of
RECK in ameloblastoma.
RECK is thought to inhibit MMP-2 at the post-transcrip-
tional level. Masui et al. [7] showed that the expression of
RECK was inverse correlation to MMP-2 activity and the
invasive capability of pancreatic cancer. Yoshida et al.
[20], using RECK mRNA-targeting siRNA interference,
reported that the expression of MMP-2 protein and its
consequent invasive capability increased in pituitary ade-
nomas cells after RECK had been downregulated. Mori
found [14] that MMP-2 activity, but not its mRNA expres-
sion, was significantly downregulated in HT1080 cells
after they were transferred into the RECK plasmid. Simi-
larly, our results showed a negative correlation between
RECK and MMP-2 protein expression, but no correlation
between RECK and MMP-2 mRNA expression in amelob-
lastoma, indicating that RECK may reduce aggression of
ameloblastomas by inhibiting MMP-2 expression at the
post-transcriptional level.
Conclusion
In summary, lower or no expression of RECK and
increased expression of MMP-2 may be associated with
worse clinical outcomes in ameloblastoma, and RECK
may help modify the behavior of ameloblastomas by reg-
ulating MMP-2 at the post-transcriptional level. Further
research is warranted to elucidate the further mechanisms
involved so as to develop appropriate therapeutic inter-
ventions.
Table 2: Relative expression levels of RECK and MMP-2 mRNA 
in KCOT and AB
nR E C K / β-acting MMP-2/β-acting
mean ± SD P mean ± SD P
KOCT 16 1.361 ± 0.145 0.000 0.099 ± 0.047 0.000
AB 22 0.131 ± 0.023 1.425 ± 0.174
Primary AB 12 0.165 ± 0.033 0.016 1.577 ± 0.249 0.959
Recurrent AB 10 0.091 ± 0.028 1.561 ± 0.208
KCOT; keratocystic odontogenic tumor, AB; ameloblastoma.
Table 3: Correlation of RECK and MMP-2 protein expression in 
ameloblastoma
RECK
MMP-2 - + ++ rP
- 1 2 8 -0.431 0.000
+1 0 6 7
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